Please login to the form below
Intra-Cellular Therapeutics
This page shows the latest Intra-Cellular Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Intra-Cellular soars on FDA approval of schizophrenia drug
Shares rocketed following the announcement. US biotech Intra-Cellular Therapeutics has scored approval for its antipsychotic drug Caplyta for the treatment of schizophrenia, to the delight of investors. . ... The approval is an early Christmas present
Latest news
-
Intra-Cellular plans schizophrenia filing in 2018
Says lumateperone could provide additional benefits over existing treatments. US biotech company Intra-Cellular Therapies says it could file its lead drug lumateperone for schizophrenia as early as next year after ... Intra-Cellular maintains this
More from news
Approximately 2 fully matching, plus 0 partially matching documents found.
Latest appointments
-
Former NICE chair Sir Michael Rawlins to lead MHRA
More recently Sir Michael has served on the board of US-based biotech Intra-Cellular Therapeutics.
-
Former NICE chair joins board of biotech
Sir Michael Rawlins joins board of Intra-Cellular Therapeutics. The former chair of England's cost-effectiveness body for medicines, Sir Michael Rawlins, has made a contentious move to the US ... His expertise in the cost-effectiveness of new
More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- New study identifies drugs that are safe to use in COVID-19 treatment
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- BMS eyes approval for second Opdivo combo in kidney cancer
- New medical communications agency BOLDSCIENCE launches
- Moderna inks R&D agreements with Vertex and Chiesi
- FDA hands BMS and bluebird bio a priority review for ide-cel
- Janssen’s EGFR-targeting treatment regimen shows early benefit in lung cancer
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- Could formulary intelligence be your brand differentiator?
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Porterhouse Medical strengthens its senior management team
PMHub
SEVEN STONES
Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....
Latest intelligence
- Could formulary intelligence be your brand differentiator?
- Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
- Improve clinical trials through patient journey mapping
- Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
Quick links
Infographics
